A broad-spectrum lipidomics screen of antiinflammatory drug combinations in human blood

10.1097/00045391-199604000-00005

10.1161/CIRCRESAHA.111.300271

10.1146/annurev-med-011209-153129

10.1172/JCI27540

10.1016/0049-3848(87)90103-4

10.1016/0049-3848(85)90027-1

10.1074/jbc.M504178200

10.1111/j.1432-1033.1987.tb13587.x

10.1007/BF02536034

10.1021/cr200246d

10.1073/pnas.0903851106

10.1172/JCI14869

10.1161/ATVBAHA.110.207449

10.1016/j.tcm.2004.04.003

10.1136/ard.62.6.501

10.1053/j.gastro.2005.10.002

10.1073/pnas.96.1.272

Capra, 2015, Transcellular biosynthesis of eicosanoid lipid mediators, Biochim Biophys Acta, 1851, 377, 10.1016/j.bbalip.2014.09.002

Rådmark, 2015, 5-Lipoxygenase, a key enzyme for leukotriene biosynthesis in health and disease, Biochim Biophys Acta, 1851, 331, 10.1016/j.bbalip.2014.08.012

10.1016/0167-4889(87)90128-5

Fu, 1990, The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes, J Biol Chem, 265, 16737, 10.1016/S0021-9258(17)44821-6

10.1002/jcp.1041460211

Niiro, 1997, Regulation by interleukin-10 and interleukin-4 of cyclooxygenase-2 expression in human neutrophils, Blood, 89, 1621, 10.1182/blood.V89.5.1621

10.1006/clin.1998.4545

Pouliot, 1998, Expression and activity of prostaglandin endoperoxide synthase-2 in agonist-activated human neutrophils, FASEB J, 12, 1109, 10.1096/fasebj.12.12.1109

10.1016/0049-3848(87)90346-X

10.1084/jem.20072329

Brash, 1985, The 5-lipoxygenase and 15-lipoxygenase of neutrophils and eosinophils, Prog Clin Biol Res, 199, 143

Nassar, 1994, Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes, J Biol Chem, 269, 27631, 10.1016/S0021-9258(18)47031-7

Turk, 1982, Arachidonic acid 15-lipoxygenase products from human eosinophils, J Biol Chem, 257, 7068, 10.1016/S0021-9258(18)34538-1

10.1038/89759

10.1016/S0891-5849(03)00440-4

10.1074/jbc.M109.011841

10.1084/jem.178.4.1347

10.2174/1568010023344959

10.1172/JCI113983

10.1152/ajpcell.00024.2014

10.1194/jlr.M060392

10.4049/jimmunol.179.1.691

10.1161/CIRCULATIONAHA.107.731398

10.1038/nm1099

10.1164/ajrccm/137.4.847

10.1164/ajrccm/146.1.96

10.1248/bpb.34.1163

Yousefi, The role of leukotrienes in immunopathogenesis of rheumatoid arthritis, Mod Rheumatol

10.1007/s12325-011-0100-7

10.1073/pnas.1406997111

10.1021/jm960803q

10.1016/S0002-9343(98)00091-6

Bingham, 2005, The cyclooxygenase-2 inhibitor GW406381X [2-(4-ethoxyphenyl)-3-[4-(methylsulfonyl)phenyl]-pyrazolo[1,5-b]pyridazine] is effective in animal models of neuropathic pain and central sensitization, J Pharmacol Exp Ther, 312, 1161, 10.1124/jpet.104.075267

10.1124/jpet.108.138776

10.1016/j.lfs.2007.11.002

10.1021/jm00024a004

10.1139/y92-107

10.1124/jpet.300.2.577

Jackson, 1999, Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies, J Pharmacol Exp Ther, 288, 286

10.1155/S0962935193000572

10.1074/jbc.M011361200

10.1093/rheumatology/keh627

Patrignani, 1994, Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases, J Pharmacol Exp Ther, 271, 1705

O’Sullivan, 1992, Lipopolysaccharide priming of alveolar macrophages for enhanced synthesis of prostanoids involves induction of a novel prostaglandin H synthase, J Biol Chem, 267, 14547, 10.1016/S0021-9258(18)42073-X

10.1002/rcm.1170

10.1101/gr.092759.109